Sonya Marshall-Gradisnik

List of Publications by Year
in descending order

52	982	489802 18	536525 29
papers	citations	h-index	g-index

53	53	53	905
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients. Journal of Translational Medicine, 2022, 20, 94.	1.8	8
2	Volumetric differences in hippocampal subfields and associations with clinical measures in myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Neuroscience Research, 2022, 100, 1476-1486.	1.3	6
3	Alteration of Cortical Volume and Thickness in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Frontiers in Neuroscience, 2022, 16, 848730.	1.4	5
4	A systematic review of nutraceutical interventions for mitochondrial dysfunctions in myalgic encephalomyelitis/chronic fatigue syndrome. Journal of Translational Medicine, 2021, 19, 81.	1.8	9
5	Systematic Review of Sleep Characteristics in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Healthcare (Switzerland), 2021, 9, 568.	1.0	5
6	A preliminary investigation of nutritional intake and supplement use in Australians with myalgic encephalomyelitis/chronic fatigue syndrome and the implications on health-related quality of life. Food and Nutrition Research, 2021, 65, .	1.2	2
7	The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP2 and NK cell function in myalgic encephalomyelitis/chronic fatigue syndrome patients. Journal of Translational Medicine, 2021, 19, 306.	1.8	9
8	Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment. Frontiers in Immunology, 2021, 12, 687806.	2.2	17
9	Diffusion tensor imaging reveals neuronal microstructural changes in myalgic encephalomyelitis/chronic fatigue syndrome. European Journal of Neuroscience, 2021, 54, 6214-6228.	1.2	18
10	Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review. International Journal of Environmental Research and Public Health, 2021, 18, 10708.	1.2	3
11	Network Analysis of Symptoms Co-Occurrence in Chronic Fatigue Syndrome. International Journal of Environmental Research and Public Health, 2021, 18, 10736.	1.2	7
12	Impact of Life Stressors on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Symptoms: An Australian Longitudinal Study. International Journal of Environmental Research and Public Health, 2021, 18, 10614.	1.2	6
13	Characterization of IL-2 Stimulation and TRPM7 Pharmacomodulation in NK Cell Cytotoxicity and Channel Co-Localization with PIP2 in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. International Journal of Environmental Research and Public Health, 2021, 18, 11879.	1.2	2
14	A systematic review of mitochondrial abnormalities in myalgic encephalomyelitis/chronic fatigue syndrome/systemic exertion intolerance disease. Journal of Translational Medicine, 2020, 18, 290.	1.8	36
15	Mapping of pathological change in chronic fatigue syndrome using the ratio of T1- and T2-weighted MRI scans. NeuroImage: Clinical, 2020, 28, 102366.	1.4	19
16	The Economic Impacts of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome in an Australian Cohort. Frontiers in Public Health, 2020, 8, 420.	1.3	21
17	A systematic review of metabolomic dysregulation in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis/Systemic Exertion Intolerance Disease (CFS/ME/SEID). Journal of Translational Medicine, 2020, 18, 198.	1.8	20
18	A systematic review of neurological impairments in myalgic encephalomyelitis/ chronic fatigue syndrome using neuroimaging techniques. PLoS ONE, 2020, 15, e0232475.	1.1	43

#	Article	IF	Citations
19	Title is missing!. , 2020, 15, e0232475.		0
20	Title is missing!. , 2020, 15, e0232475.		0
21	Title is missing!. , 2020, 15, e0232475.		0
22	Title is missing!. , 2020, 15, e0232475.		0
23	Title is missing!. , 2020, 15, e0232475.		0
24	Title is missing!. , 2020, 15, e0232475.		0
25	Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients. Frontiers in Immunology, 2019, 10, 2545.	2.2	22
26	Intra brainstem connectivity is impaired in chronic fatigue syndrome. NeuroImage: Clinical, 2019, 24, 102045.	1.4	37
27	A systematic review of cytokines in chronic fatigue syndrome/myalgic encephalomyelitis/systemic exertion intolerance disease (CFS/ME/SEID). BMC Neurology, 2019, 19, 207.	0.8	29
28	Identification and characterisation of transient receptor potential melastatin 2 and CD38 channels on natural killer cells using the novel application of flow cytometry. BMC Immunology, 2019, 20, 14.	0.9	1
29	Prevalence and characteristics of chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) in Poland: a cross-sectional study. BMJ Open, 2019, 9, e023955.	0.8	30
30	Epidemiology of paediatric chronic fatigue syndrome in Australia. Archives of Disease in Childhood, 2019, 104, 733-738.	1.0	5
31	A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome. Systematic Reviews, 2019, 8, 279.	2.5	42
32	Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients. Journal of Translational Medicine, 2019, 17, 401.	1.8	13
33	Reduced glycolytic reserve in isolated natural killer cells from Myalgic encephalomyelitis/chronic fatigue syndrome patients: A preliminary investigation. Asian Pacific Journal of Allergy and Immunology, 2019, 37, 102-108.	0.2	11
34	Hyperintense sensorimotor T1 spin echo MRI is associated with brainstem abnormality in chronic fatigue syndrome. NeuroImage: Clinical, 2018, 20, 102-109.	1.4	29
35	Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation. BMC Pharmacology & Toxicology, 2018, 19, 12.	1.0	3
36	Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. Molecular Medicine, 2018, 24, 44.	1.9	29

#	Article	IF	Citations
37	Investigation of mast cell toll-like receptor 3 in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Systemic Mastocytosis participants using the novel application of autoMACS magnetic separation and flow cytometry. Asian Pacific Journal of Allergy and Immunology, 2018, 36, 257-264.	0.2	2
38	Novel characterisation of mast cell phenotypes from peripheral blood mononuclear cells in chronic fatigue syndrome/myalgic encephalomyelitis patients. Asian Pacific Journal of Allergy and Immunology, 2017, 35, 75-81.	0.2	4
39	Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome. The Application of Clinical Genetics, 2016, 9, 39.	1.4	44
40	Epidemiological characteristics of chronic fatigue- syndrome/myalgic encephalomyelitis in Australian patients. Clinical Epidemiology, 2016, 8, 97.	1.5	37
41	A Preliminary Comparative Assessment of the Role of CD8+ T Cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis and Multiple Sclerosis. Journal of Immunology Research, 2016, 2016, 1-8.	0.9	12
42	Single nucleotide polymorphisms and genotypes of transient receptor potential ion channel and acetylcholine receptor genes from isolated B lymphocytes in myalgic encephalomyelitis/chronic fatigue syndrome patients. Journal of International Medical Research, 2016, 44, 1381-1394.	0.4	19
43	A targeted genome association study examining transient receptor potential ion channels, acetylcholine receptors, and adrenergic receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. BMC Medical Genetics, 2016, 17, 79.	2.1	17
44	ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56dimCD16+ and CD56brightCD16dim/â^' natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. Journal of Translational Medicine, 2016, 14, 97.	1.8	31
45	Severity Scales for Use in Primary Health Care to Assess Chronic Fatigue Syndrome/Myalgic Encephalomyelitis. Health Care for Women International, 2016, 37, 671-686.	0.6	5
46	Longitudinal analysis of immune abnormalities in varying severities of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients. Journal of Translational Medicine, 2015, 13, 299.	1.8	40
47	Serum Immune Proteins in Moderate and Severe Chronic Fatigue Syndrome/Myalgic Encephalomyelitis Patients. International Journal of Medical Sciences, 2015, 12, 764-772.	1.1	28
48	Sudden infant death syndrome: Postulated role of impaired vasoactive neuropeptide-related inflammatory modulation. Journal of Pediatric Infectious Diseases, 2015, 05, 027-035.	0.1	1
49	Characterisation of cell functions and receptors in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis (CFS/ME). BMC Immunology, 2015, 16, 35.	0.9	46
50	The adoption of chronic fatigue syndrome/myalgic encephalomyelitis case definitions to assess prevalence: a systematic review. Annals of Epidemiology, 2013, 23, 371-376.	0.9	37
51	The prevalence of chronic fatigue syndrome/ myalgic encephalomyelitis: a meta-analysis. Clinical Epidemiology, 2013, 5, 105.	1.5	151
52	Anabolic androgenic steroids effects on the immune system: a review. Open Life Sciences, 2009, 4, 19-33.	0.6	21